Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

261 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile.
Eide CA, Adrian LT, Tyner JW, Mac Partlin M, Anderson DJ, Wise SC, Smith BD, Petillo PA, Flynn DL, Deininger MW, O'Hare T, Druker BJ. Eide CA, et al. Among authors: deininger mw. Cancer Res. 2011 May 1;71(9):3189-95. doi: 10.1158/0008-5472.CAN-10-3224. Epub 2011 Apr 19. Cancer Res. 2011. PMID: 21505103 Free PMC article.
Activating alleles of JAK3 in acute megakaryoblastic leukemia.
Walters DK, Mercher T, Gu TL, O'Hare T, Tyner JW, Loriaux M, Goss VL, Lee KA, Eide CA, Wong MJ, Stoffregen EP, McGreevey L, Nardone J, Moore SA, Crispino J, Boggon TJ, Heinrich MC, Deininger MW, Polakiewicz RD, Gilliland DG, Druker BJ. Walters DK, et al. Among authors: deininger mw. Cancer Cell. 2006 Jul;10(1):65-75. doi: 10.1016/j.ccr.2006.06.002. Cancer Cell. 2006. PMID: 16843266 Free article.
Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib.
Griswold IJ, MacPartlin M, Bumm T, Goss VL, O'Hare T, Lee KA, Corbin AS, Stoffregen EP, Smith C, Johnson K, Moseson EM, Wood LJ, Polakiewicz RD, Druker BJ, Deininger MW. Griswold IJ, et al. Among authors: deininger mw. Mol Cell Biol. 2006 Aug;26(16):6082-93. doi: 10.1128/MCB.02202-05. Mol Cell Biol. 2006. PMID: 16880519 Free PMC article.
SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib.
O'Hare T, Eide CA, Tyner JW, Corbin AS, Wong MJ, Buchanan S, Holme K, Jessen KA, Tang C, Lewis HA, Romero RD, Burley SK, Deininger MW. O'Hare T, et al. Among authors: deininger mw. Proc Natl Acad Sci U S A. 2008 Apr 8;105(14):5507-12. doi: 10.1073/pnas.0800587105. Epub 2008 Mar 26. Proc Natl Acad Sci U S A. 2008. PMID: 18367669 Free PMC article.
Toward a cure for chronic myeloid leukemia.
O'Hare T, Deininger MW. O'Hare T, et al. Among authors: deininger mw. Clin Cancer Res. 2008 Dec 15;14(24):7971-4. doi: 10.1158/1078-0432.CCR-08-1486. Clin Cancer Res. 2008. PMID: 19088011 Free PMC article. No abstract available.
261 results